Forms

LEUVEN, Belgium - - Recruitment on Track for ThromboGenics' Lead Product for the Non-Surgical Treatment of Eye Disease With No Reported Safety Issues ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that its lead product microplasmin, which is in Phase III trials for the treatment of vitreomacular adhesion, is progressing according to schedule.

DENVER - Tata Technologies' knowledge management application provides single, easy-to-navigate access point i GET IT(R), the global engineering knowledge management application from Tata Technologies, announces its support of Ford Motor Company's global "Next Generation" release of CAD/CAM/CAE/PIM (C3P-NG) software tools.

LUGANO, Switzerland - A new release of the NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology on Antiemesis recommends palonosetron as the "preferred" 5-HT3 antagonist in combination with aprepitant and dexamethasone for prevention of emesis in highly emetic risk chemotherapy.

LUDWIGSHAFEN, Germany - All over the world cows, goats, sheep and other mammals are industriously milked every day to provide us with a whole range of dairy products.